Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Intravenous Endothelin-1 Infusion Does Not Induce Aura or Headache in Migraine Patients With Aura

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Sumatriptan Does Not Antagonize CGRP-Induced Symptoms in Healthy Volunteers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The Stereotypical Image of a Person With Migraine According to Mass Media

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Two-Hour CGRP Infusion Causes Gastrointestinal Hyperactivity: Possible Relevance for CGRP Antibody Treatment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Vancouver Declaration II on Global Headache Patient Advocacy 2019

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Low frequency activation of the sphenopalatine ganglion does not induce migraine-like attacks in migraine patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Ictal neck pain investigated in the interictal state - a search for the origin of pain

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Neck pain and headache after whiplash injury: a systematic review and meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: To investigate whether intravenously infused provokes migraine aura and migraine headache in migraine patients with aura.

BACKGROUND: Migraine with aura has been associated with endothelial dysfunction and increased stroke risk. The initiating mechanism of migraine aura symptoms is not known. Experimental provocation of migraine headache using vasoactive peptides has provided tremendous advances in the understanding of migraine pathophysiology but substances that can induce migraine aura have not been identified. Endothelin-1 (ET-1), an endogenous, potent vasoconstrictor peptide released from the vascular endothelium, has been proposed to trigger migraine aura. This hypothesis is based on reports of increased plasma ET-1 levels early during the migraine attacks and the observation that ET-1 applied to the cortical surface potently induces the cortical spreading depolarization, the underlying electrophysiological phenomenon of migraine aura, in animals. Further, endothelial damage due to, for example, carotid puncture and vascular pathology is known to trigger aura episodes.

METHODS: We investigated whether intravascular ET-1 would provoke migraine aura in patients. Using a two-way crossover, randomized, placebo-controlled, double-blind design, we infused high-dose (8 ng/kg/minutes for 20 minutes) intravenous ET-1 in patients with migraine with typical aura. The primary end-point was the difference in incidence of migraine aura between ET-1 and placebo. Experiments were carried out at a public tertiary headache center (Danish Headache Center, Rigshospitalet Glostrup, Denmark).

RESULTS: Fourteen patients received intravenous ET-1. No patients reported migraine aura symptoms or migraine headache during or up to 24 hours following the ET-1 infusion. Four patients reported mild to moderate headache only on the ET-1 day, 3 patients reported moderate headache on the placebo day, and 1 patient reported mild headache on both days. No serious adverse events occurred during or after infusion.

CONCLUSIONS: Provocation of migraine aura by procedures or conditions involving vascular irritation is unlikely to be mediated by ET-1.

OriginalsprogEngelsk
TidsskriftHeadache
Vol/bind60
Udgave nummer4
Sider (fra-til)724-734
Antal sider11
ISSN0017-8748
DOI
StatusUdgivet - apr. 2020

Bibliografisk note

© 2020 American Headache Society.

ID: 59482976